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P U B L I S H E D B Y E L S E V I E R I N C .LettersA Persisting Dilemma for
Triple Antithrombotic
Therapy
Are We Close to Finding the Correct Answer?We have read with much interest the article by Lam-
berts et al. (1), who reported on oral anticoagulation
(OAC) and antiplatelets in atrial ﬁbrillation (AF) pa-
tients after myocardial infarction (MI) and coronary
intervention, and who concluded that OAC and clo-
pidogrel were equal or better on both beneﬁt and
safety outcomes compared with triple therapy. The
study group included 12,165 AF patients hospitalized
with MI and/or who underwent percutaneous coro-
nary intervention (PCI) between 2001 and 2009. We
congratulate the investigators for their work, which
evaluated the effects of antithrombotic therapy in
real-life patients in a nationwide setting, regardless
of race, employment, health insurance coverage,
and socioeconomic status. However, there are few
aspects that, in our opinion, need clariﬁcation.
Recent Consensus Documents recommend triple
therapy in patients with AF presenting with MI or
those undergoing PCI, including OAC plus aspirin
100 mg/day and clopidogrel 75 mg/day in the short
term, followed by longer therapy with OAC plus a
single antiplatelet drug, and OAC for only 1 year after
the index event (2). According to European Society of
Cardiology Guidelines, triple therapy (OAC, aspirin,
clopidogrel) should be considered in the short term (3
to 6 months) or longer in selected patients at low
bleeding risk following MI with or without PCI
in patients with AF (3). There is no difference between
the two stent types in terms of antithrombotic treat-
ment. In case of elective PCI, antithrombotic treat-
ment may vary. Namely, clopidogrel should be
considered in combination with warfarin plus aspirin
for a minimum of 1 month after implantation of a
bare-metal stent (BMS), but longer with a drug-
eluting stent (DES). Furthermore, duration of triple
therapy may change by the type of DES used (at
least 3 months for a sirolimus-eluting stent and at
least 6 months for a paclitaxel-eluting stent).
After DES implantation, delayed endothelialization
causes late stent thrombosis and raises safetyconcerns; there are studies that suggest that DESs are
associated with an increased rate of this event
compared with BMSs (4,5). For this reason, optimal
antiplatelet therapy after PCI with DES requires a
long-term combination of aspirin and clopidogrel.
There are no details in the study on which stent
types were used for PCI. If stent types were pre-
dominantly DESs, the study proves that the beneﬁcial
recommendations provide practical guidance for cli-
nicians in managing a complex problem of coexisting
AF and MI with PCI.Mehmet Aytürk, MD
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115:1440–55.REPLY: A Persisting Dilemma for
Triple Antithrombotic Therapy
Are We Close to Finding the Correct Answer?In response to our article (1), Dr. Aytürk and col-
leagues emphasize that the type of stent might affect
the risk of stent thrombosis and consequently the
